Introduction Metabolic syndrome (MetS) is a collection of interrelated cardiometabolic abnormalities, including central adiposity, hyperglycemia, hypertension, hypertriglyceridemia, and low level of high-density lipoprotein cholesterol (HDL-C). These features are strongly linked to the development of type 2 diabetes (T2D) and cardiovascular disease and increased mortality (1). This condition is a global epidemic disorder affecting about 20-25% of adults worldwide (2).